BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19432125)

  • 1. [Osteoporosis treatment in patients with hyperthyroidism].
    Saito J; Nishikawa T
    Nihon Rinsho; 2009 May; 67(5):1011-6. PubMed ID: 19432125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Graves' disease and bone metabolism].
    Sato K
    Nihon Rinsho; 2006 Dec; 64(12):2317-22. PubMed ID: 17154099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Osteoporosis in patients with hyperthyroidism].
    Kitahama S; Ishii T; Wada S
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():711-7. PubMed ID: 15035214
    [No Abstract]   [Full Text] [Related]  

  • 4. Thyroid hormones: beneficial or deleterious for bone?
    Lakatos P
    Calcif Tissue Int; 2003 Sep; 73(3):205-9. PubMed ID: 14667131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Growth hormone deficiency, its influence on bone mineral density and risk of osteoporotic fractures].
    Kuzma M; Payer J
    Cas Lek Cesk; 2010; 149(5):211-6. PubMed ID: 20629339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid diseases and bone health.
    Williams GR; Bassett JHD
    J Endocrinol Invest; 2018 Jan; 41(1):99-109. PubMed ID: 28853052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bone changes in thyrotoxicosis].
    Ejima E; Fujiyama K; Kiriyama T; Eguchi K
    Nihon Rinsho; 1998 Jun; 56(6):1587-90. PubMed ID: 9648486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Osteoporosis in patients with thyroid disease].
    Kitahama S; Wada S
    Nihon Rinsho; 2002 Mar; 60 Suppl 3():451-8. PubMed ID: 11979942
    [No Abstract]   [Full Text] [Related]  

  • 10. [Thyroid hormone and bone mass].
    Nóvoa Mogollón FJ
    Med Clin (Barc); 1994 Nov; 103(18):695-6. PubMed ID: 7808076
    [No Abstract]   [Full Text] [Related]  

  • 11. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women.
    Garnero P; Delmas PD
    J Musculoskelet Neuronal Interact; 2004 Mar; 4(1):50-63. PubMed ID: 15615078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Methimazole versus methimazole and diphosphonates in hyperthyroid and osteoporotic patients].
    Lupoli GA; Fittipaldi MR; Fonderico F; Panico A; Colarusso S; Di Micco L; Cavallo A; Costa L; Paglione A; Lupoli G
    Minerva Endocrinol; 2005 Jun; 30(2):89-94. PubMed ID: 15988404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
    J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism.
    Bassett JH; O'Shea PJ; Sriskantharajah S; Rabier B; Boyde A; Howell PG; Weiss RE; Roux JP; Malaval L; Clement-Lacroix P; Samarut J; Chassande O; Williams GR
    Mol Endocrinol; 2007 May; 21(5):1095-107. PubMed ID: 17327419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of osteoporosis.
    Rosen CJ
    Baillieres Best Pract Res Clin Endocrinol Metab; 2000 Jun; 14(2):181-93. PubMed ID: 11035901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skeletal diseases in Cushing's syndrome: osteoporosis versus arthropathy.
    Kaltsas G; Makras P
    Neuroendocrinology; 2010; 92 Suppl 1():60-4. PubMed ID: 20829620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thyroid and osteoporosis].
    Földes J; Lakatos P
    Orv Hetil; 1996 Jun; 137(25):1347-54. PubMed ID: 8757081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The influence of thyrotoxicosis and thyroxine therapy on the risk of osteoporosis].
    Zatońska K; Bolanowski M
    Pol Merkur Lekarski; 2000 May; 8(47):356-9. PubMed ID: 10944962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New mechanisms and targets in the treatment of bone fragility.
    Martin TJ; Seeman E
    Clin Sci (Lond); 2007 Jan; 112(2):77-91. PubMed ID: 17155930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers of bone health and osteoporosis risk.
    Eastell R; Hannon RA
    Proc Nutr Soc; 2008 May; 67(2):157-62. PubMed ID: 18412989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.